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A
nyone who has experienced the 
assault of the pharmaceutical 
industry’s marketing campaigns 
would appreciate Jennifer Berry’s 
one-person play Big Pharma: The Rise 
of the Anti-Depressant Drug Industry and 
the Loss of a Generation. Since the mid-
1990s, spending on drug promotion 
has grown steadily, reaching $21 billion 
in 2002. Berry explores the fallout of 
this expanded marketing blitz through 
the eyes of its masterminds, unwitting 
(and complicit) abettors, and victims 
through her portrayal of an advertising 
executive, a physician, and women and 
children who are prescribed heavily 
marketed antidepressants.
A primary target of the 
pharmaceutical industry, physicians 
receive not just advertising 
materials but ofﬁ  ce visits from 
drug representatives. Berry’s 
physician, depicted as a pawn of the 
pharmaceutical industry, gratefully 
accepts the free drug samples, the 
free lunches, and the pharmaceutical 
industry–sponsored trips to tropical 
islands. In fact, the pharmaceutical 
industry woos physicians with 
educational dinners, honoraria for 
participating in conference calls, 
consulting fees for participating in 
speakers’ bureaus, research funding, 
and payments to write scientiﬁ  c 
publications. And physicians act as 
agents of the pharmaceutical industry 
in many ways, such as giving talks 
that favor a company’s product, 
participating in clinical trials that 
increase physicians’ exposure to a new 
drugs or new indications for old drugs, 
and publishing research articles that 
are ﬁ  nanced and, in fact, written by 
pharmaceutical company employees 
[1].
In addition to reaching physicians 
directly, the industry promotes 
consumer familiarity with particular 
drugs. In 2002, almost $3 billion of the 
industry’s drug promotion budget was 
spent on direct-to-consumer advertising 
[2], with advertising venues spanning 
from print media to radio, television, 
and the Internet [3]. In her play, Berry 
notes that direct-to-consumer drug 
advertising skyrocketed in the United 
States after a 1997 change in the Food 
and Drug Administration guidelines 
for advertising. She also gives a nod to 
the nearly incomprehensible patient 
information that must be provided with 
each ad: “We tell them to buy it, then 
tell them why not to buy it.” And, the 
“why not” is presented in an illegible 
font in print ads, or high-speed chatter 
for television and radio.
Less obvious marketing strategies 
include using opinion leaders, and 
sponsoring education programs, 
scientiﬁ  c research, publications, 
and professional meetings. The 
pharmaceutical industry has also 
extended its inﬂ  uence to clinical 
trial administration, research design, 
regulatory lobbying, physician and 
patient education, drug pricing, 
pharmacy distribution, and drug 
compliance [4].
There is a wide range of evidence 
suggesting that all of these marketing 
strategies inﬂ  uence physician 
prescribing and affect patient attitudes 
and behavior. Interactions with the 
pharmaceutical industry increase the 
likelihood of physicians prescribing 
inappropriately or making formulary 
requests for the company’s product 
[5–9]. Yet health professionals at 
all levels of training tend to believe 
that they are not inﬂ  uenced by the 
drug industry [10–13]. For instance, 
research suggests that most health-care 
professionals think information from 
drug companies is biased, but many 
think it is useful nonetheless. With 
regard to direct-to-consmer advertising, 
most doctors are opposed to it, 
primarily because it negatively impacts 
the doctor–patient relationship and 
pressures doctors to prescribe drugs 
they might not otherwise use [2,14].
Empirical evidence regarding 
direct-to-consumer advertising shows 
that it acts as promotion rather than 
education, often includes inaccurate, 
misleading, or unbalanced information, 
frequently includes emotional appeals 
to anxiety about illness, underplays 
risks, omits mention of costs, and tends 
to promote the “medicalization” of 
normal health and minor ailments 
[15–17]. And consumers tend to have 
positive views of drug advertisements, 
show awareness of advertisements, 
and exhibit a willingness to discuss 
or request from their doctor a drug 
they have seen advertised [15,18,19]. 
Pointedly, Berry’s physician fears his 
patients will sue if he doesn’t prescribe 
the drugs they ask for.
The notion that the pharmaceutical 
industry creates diseases or “disorders” 
when none exist surfaces as a major 
theme of the play. Berry’s advertising 
executive proudly displays direct-
to-consumer advertisements for 
antidepressants. The executive explains 
that she “can’t just say ‘buy drugs,’” so 
the advertisers develop a campaign that 
preys on women with societal problems, 
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such as stress or homelessness. Clearly, 
pharmaceutical marketing practices 
impact deﬁ  nitions of social concern, 
health, and illness. For example, 
Moynihan and Cassels [16] and 
Moynihan and Henry [17] discuss 
how the expansion of pharmaceutical 
marketing practices leads to different 
forms of disease mongering: aspects 
of ordinary life, such as menopause, 
are treated as medical conditions; 
mild problems are portrayed as serious 
illnesses, as occurred with the drug 
company–sponsored promotion of 
irritable bowel syndrome; and risk 
factors, such as high cholesterol and 
osteoporosis, are framed as diseases. 
One example touched on in Berry’s 
play is the condition of “social anxiety 
disorder,” which is diagnosed in a poor, 
unemployed woman who is having 
trouble with job interviews [16]. Berry 
dramatizes the solution—prescribe an 
antidepressant rather than ﬁ  nd a job—
by solving every character’s problem 
with a drug prescription.
And it is Berry’s patient characters 
that have the most impact. The patients 
are portrayed as victims not only 
of a proﬁ  t-seeking pharmaceutical 
industry, but of society in general. 
Berry describes the pharmaceutical 
industry’s target market as women 
who are subjected to sexism, racism, 
and social inequalities. She describes 
how the pharmaceutical industry has 
transformed these societal problems 
into medical “disorders” that can 
be treated with a pill—in this case 
an antidepressant. Children who 
dare to be different or energetic are 
also labeled with a disorder. Berry’s 
soliloquy poignantly describes how 
antidepressants transform vibrant 
individuals into quiet, passive people 
with a lack of affect. Her description 
of the side effects of antidepressants is 
completely accurate. Unfortunately, the 
play does give the impression that most 
women are not strong enough to help 
themselves. But, of course, this is what 
the pharmaceutical industry is counting 
on.
My favorite part of the play is when 
Berry acts one half of a conversation 
with an elderly woman who lived 
through the Great Depression. She 
describes how everyone was sad, but, 
together, people survived. Berry 
contrasts this to our current era of the 
“anti-Depression,” when unhappiness 
is considered a disease that must be 
eradicated.
I have to admit that Berry’s 
performance left me a bit depressed. 
I was depressed by the fact that the 
pharmaceutical industry manages to 
take advantage of societal problems 
to market their products and increase 
their proﬁ  ts. At the same time, the 
industry’s tactics were exposed and 
the audience had a chance to think 
about how to channel unhappiness to 
confront our real problems and not just 
treat the symptom. After the play, I did 
have an urge to go home and be sad for 
a while...but not to pop any pills.  
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